<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649190</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-13-0685-IB-CTIL-B</org_study_id>
    <nct_id>NCT04649190</nct_id>
  </id_info>
  <brief_title>Post-TAVI Coronary Access Study</brief_title>
  <acronym>PTCA</acronym>
  <official_title>Post-TAVI Coronary Access Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary access after trans-catheter aortic valve implantation (TAVI) remains a major&#xD;
      challenge. With the evolution of TAVI procedure and the inclusion of lower-risk patients with&#xD;
      aortic stenosis, future coronary access is an even greater concern, because this lower-risk&#xD;
      patient group has a greater cumulative risk of requiring coronary angiography for acute&#xD;
      coronary events compared to their octogenarian counterparts.&#xD;
&#xD;
      It is only speculated that the intra-annular position of the self-expandable valves together&#xD;
      with the frame covering coronary ostia would impose a significant technical challenge as&#xD;
      compared to the balloon-expandable valve (1). However, this remains to be proven. With any&#xD;
      valve used, increased catheter manipulations may result in longer fluoroscopy times, larger&#xD;
      volumes of contrast, and reduced imaging quality due to non-selective injections (2).&#xD;
&#xD;
      Although complex, coronary procedures after TAVR are considered relatively safe and feasible&#xD;
      on experience hands (3-6). A number of techniques to increase the likelihood of successful&#xD;
      coronary intubation after TAVR have been described in the published reports and include the&#xD;
      use of intracoronary guidewires (1), as well as balloon-assisted tracking with guideliner&#xD;
      extension (7). It is therefore essential to fully understand the potential challenges of&#xD;
      coronary angiography and PCI in this specific patient population. Guidance by a specific&#xD;
      algorithm may help to overcome difficulties in coronary angiography and facilitate selective&#xD;
      coronary intubation particularly during primary PCI (8).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2010</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PCI device success</measure>
    <time_frame>5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful delivery, balloon expansion, and deployment of the first assigned device, at the intended target lesion</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful withdrawal of the device delivery system</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attainment of a final in-stent or in-scaffold residual stenosis of &lt;20%</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final TIMI flow</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful selective engagement of guiding catheter</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of procedural complications</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural mortality</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>TAVI</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI</intervention_name>
    <description>Coronary access for PCI after TAVI</description>
    <arm_group_label>TAVI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who underwent TAVI at any time point prior to index PCI procedure, and who have&#xD;
        clinical indication for PCI will be included in the present study. Consecutive subjects of&#xD;
        both genders will be enrolled at various sites in Europe, United States and Asia (See&#xD;
        Appendix 1). The study procedures, clinical management and follow up will be done at each&#xD;
        participating center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Prior TAVI for aortic stenosis or regurgitation in bicuspid or tricuspid valve&#xD;
&#xD;
          2. Clinical indication for PCI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior TAVI valve-in-valve procedures&#xD;
&#xD;
          2. Prior TAVI-in-TAVI procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Israel Barbash, MD</last_name>
      <phone>97235305273</phone>
      <email>ibarbash@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Issi Barbash</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

